The Nephron journals/Nephron journals · 2008 · 27 citations · 0 references
Life SciencesImmunologyPathologyClinical ImmunologyImmunotherapyTransplant ImmunologyAcute RejectionAllograft RejectionAntibody-mediated RejectionGraft RejectionTransplant ImmunotherapyTransplant RejectionAntibody-mediated Rejection TherapyHumoral RejectionImmunologic Response To AllograftT-cell Mediated RejectionTreatment Of Rejection Episodes
Antimouse antibody is produced from 40 to 68% of the time after administration of Orthoclone OKT3. In patients treated with OKT3, however, if the concomitant immunosuppression is not decreased, the incidence of the antibody production is reduced to 40%. Similarly, 33% of patients developed antihorse antibody after the initial antithymocyte globulin (ATG) administration. Most of the time, the antibody production is low-titered for both OKT3 and ATG.